Based on russ h's 2 uploaded records, what should I know

Understanding Your [ID removed] Key Findings

Looking at your two documents, here's what's important to understand about your pancreatic cancer situation:

Your Treatment Journey So Far

Your records show you've had an aggressive treatment approach:

• Neoadjuvant chemotherapy (FOLFIRINOX before surgery) to shrink the tumor
• Whipple surgery (August 2022) to remove the pancreatic head
• Adjuvant chemotherapy (FOLFIRI after surgery) to eliminate remaining cancer cells
• Radiation therapy to the vascular groove area
• No evidence of disease (NED) for most of 2023-2024, but lung metastasis appeared late 2024

You're now enrolled in a clinical trial combining FOLFIRINOX with RMC-6236 starting [date removed].

---

Your Molecular Profile: The Critical Part

Your genetic testing reveals several important mutations that are actionable—meaning they can guide treatment decisions:

1. RAF1 Fusion (PDZRN3::RAF1) — RARE & SIGNIFICANT

• This is uncommon in pancreatic cancer and suggests your tumor may respond to MEK inhibitors (drugs that block the MAPK pathway)
• Your records specifically note Trametinib as a potential option, though insurance denied it
• This is a key finding your team should prioritize

2. MTAP Loss — Opens Targeted Therapy Options

• Suggests eligibility for PRMT5-targeted therapies like:
  • AMG 193 + IDE397 (clinical trial NCT05975073)
  • MRTX1719
• These are newer, precision-medicine approaches

3. TP53 Mutation (Y163C) — 25.1% in blood

• This tumor suppressor gene is mutated in your cancer
• Detected at relatively high levels in your circulating tumor DNA (cfDNA)
• Clinical trial NCT05109975 (Debio 0123) targets this mutation

4. CDK6 Amplification — Medium level

• Suggests potential benefit from CDK4/6 inhibitors like Abemaciclib
• Multiple clinical trials available in NYC area (TAPUR, NCT05238922, others)

5. BCOR Mutation (Y376fs) — 31.3% in blood

• This is a frameshift mutation (disrupts the protein)
• Currently no FDA-approved therapies target this directly

---

Important Context: KRAS Wild-Type Status

This is crucial: You are KRAS wild-type (no KRAS mutation). This means:

• The RMC-6236 drug in your current trial targets KRAS G12C mutations specifically
• Since you don't have this mutation, the drug may have limited efficacy for you personally
• This is a legitimate clinical question to discuss with your team

According to Dr. [removed] Strickler's expert guidance on pancreatic cancer precision medicine, KRAS mutations drive 87% of pancreatic cancers, but your tumor is in the remaining 13% without KRAS alterations. This actually opens different therapeutic pathways.

---

Your Biomarker Summary

| Finding | Value | What It Means | |---------|-------|---------------| | Tumor Fraction | 18.1% | Moderate amount of tumor DNA in blood—good for monitoring | | TMB (Tumor Mutational Burden) | 2.85 mut/Mb | Low-to-moderate; below threshold for checkpoint inhibitors alone | | MSI Status | Not detected | Microsatellite stable (typical for pancreatic cancer) | | PDL1 | High | May benefit from immunotherapy combinations | | Immune Microenvironment | Immune Desert | Limited immune cells in tumor—explains why immunotherapy alone may be insufficient |

---

Critical Questions for Your Oncology Team

Based on your records, here are specific questions you should ask:

1. About your current trial:

   • "Since I'm KRAS wild-type, how will you monitor whether RMC-6236 is actually working for me? What's the plan if it's not effective?"
   • "What biomarkers or imaging will you use to assess response?"

2. About RAF1 fusion (your most actionable finding):

   • "Can we discuss MEK inhibitors like Trametinib for my RAF1 fusion? Why was this deprioritized?"
   • "Are there clinical trials for RAF1-fusion pancreatic cancer I should consider?"
   • "What's the status of my insurance appeal for Trametinib, or should we explore compassionate use?"

3. About MTAP loss:

   • "Am I eligible for AMG 193 or MRTX1719 trials? Do any have sites in NYC?"
   • "How would MTAP-targeted therapy be sequenced with my current treatment?"

4. About monitoring:

   • "Should we repeat Guardant360 liquid biopsy during the trial to track tumor DNA levels?"
   • "What would indicate it's time to move off this trial to a different approach?"

5. About next steps:

   • "If RMC-6236 + FOLFIRINOX doesn't work, what's your sequencing strategy given my RAF1 fusion and MTAP loss?"
   • "Are there combination approaches (e.g., MEK inhibitor + chemotherapy) we should consider?"

---

Key Takeaway

Your records show you have a molecularly complex tumor with multiple actionable mutations—this is actually good news in precision oncology terms. You're not just getting standard chemotherapy; your team has identified specific genetic drivers they can potentially target.

However, the mismatch between your KRAS wild-type status and the RMC-6236 trial is worth clarifying. Your RAF1 fusion is your most distinctive finding and deserves focused attention.

According to NCCN Guidelines for Pancreatic Cancer, molecular profiling and genetic testing are now recommended for all patients, and your team has done this well. The next step is ensuring your treatment plan fully leverages these findings.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.